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Introduction 
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and the sympathetic nervous system (SNS) in 
health and diseases (e.g. cardiovascular, renal), 
with a special focus on these two systems 
interaction during HS intake in healthy 
Abstract 
It is well accepted that a number of cardiovascular (CV) and renal diseases are characterized by the long-term 
activation of both the renin-angiotensin system (RAS) and the sympathetic nervous system (SNS), which also 
contribute to the pathophysiology of structural and functional CV abnormalities as well as to the final clinical 
outcome. Moreover, there is a growing body of conclusive evidence that these systems do not operate 
independently, but interact at different levels throughout the CV system. The mediation of renin release from 
juxtaglomerular epithelioid (JGE) cells in kidney by SNS is well established and accepted. On the other hand, in 
recent years it became evident that RAS, by its main effect or angiotensin II (Ang II), induces SNS activity in 
various organs and tissues. Thus, there is a growing effort to clarify pathophysiological mechanisms of 
interaction and a more evident mutual potentiation of these two systems in different pathological states. Since 
it became evident that a high salt (HS) intake, which is a major risk factor for hypertension development, has a 
deleterious impact on vascular and endothelial functions (even in the absence of blood pressure changes), it 
became necessary to investigate and clarify the effect of HS loading on major regulating systems—RAS and 
SNS—precisely in healthy individuals. The present review aimed to summarize the interactions between the 
RAS and SNS in health and diseases (e.g. cardiovascular, renal), with a special focus on these two systems’ 
interaction during HS intake in a healthy normotensive population. 
(Stupin A, Drenjancevic I, Rasic L, Cosic A, Stupin M. A Cross-Talk between the Renin-Angiotensin and 
Adrenergic Systems in Cardiovascular Health and Disease. SEEMEDJ 2017;1(1);90-107) 
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individuals. The mediation of renin release from 
JGE cells in kidney by β1-adrenergic receptors 
activation is well established and accepted (1). 
However, there is a growing interest to 
understand how RAS affects SNS activity, and to 
evaluate whether these two systems potentiate 
each other’s effects. It became evident that RAS, 
by its main effector, angiotenin II (Ang II), 
increases SNS activity in various organs and 
tissues (e.g. the central nervous system, the 
adrenal medulla, the sympathetic ganglia and 
the sympathetic nerve endings), and that this 
interaction is mediated mostly by the Ang II 
receptors type1 (AT1 receptors) located at the 
sympathetic nerve endings (2). The suggested 
physiological feedback loop in RAS-SNS 
interrelation is summarized in Figure 1. Most of 
these findings were brought by studies 
investigating the activity of these two systems in 
hypertension, chronic heart failure and/or 
chronic kidney disease (3, 4). Even though HS 
intake unequivocally suppresses RAS activity, 
the effect of HS intake on SNS activity that is 
independent of blood pressure changes is still 
not completely understood. 
The role of the renin-angiotensin 
system in the cardiovascular 
physiological control system  
The RAS is one of the most important hormonal 
systems which plays a key role in the arterial 
blood pressure, tissue perfusion, and 
extracellular volume homeostatic regulation, as 
well as in the regulation of neuronal and 
endocrine functions related to CV control (5, 6). 
RAS consists of a cascade of functional proteins 
and exhibits its effects through the effector 
molecule Ang II. In this cascade, the first is a 
release of an aspartyl protease called renin, 
which is synthesized and released from renal 
JGE cells located in the afferent and efferent 
arterioles of the renal glomerulus (1). Renin 
release is stimulated by various stimuli including 
decreased renal perfusion pressure (1), 
increased renal sympathetic nerves activity and 
decreased NaCl delivery to the macula densa of 
the juxtaglomerular apparatus (5, 6). Renin 
cleaves angiotensinogen, which is synthesized 
by hepatocytes, to form the inactive 
decapeptide angiotensin I (Ang I) (7, 8). Ang I is 
converted to the active octapeptide Ang II by 
angiotensin-converting enzyme (ACE) and non-
ACE pathways (9, 10). Non-ACE pathways 
include Ang II production viae.g. chymase, which 
can be manifested in hypertensive patients 
treated with ACE inhibitors who have increased 
Ang II levels despite their therapy, a 
phenomenon called ‘angiotensin escape’ (11). To 
carry out its biological functions, Ang II binds to 
two specific and ubiquitous G-protein coupled 
receptors, Ang receptor type I (AT1) and type II 
(AT2) (12, 13).AT1 receptors mediate most of the 
established physiological effects of ANG II 
including actions on CV system 
(vasoconstriction, increased blood pressure, 
increased cardiac contractility, vascular and 
cardiac hypertrophy), kidneys (sodium 
reabsorption in renal tubule, inhibition of renin 
release), adrenal cortex (aldosterone synthesis) 
and SNS (1, 5, 6). AT2 receptors are generally 
assumed to counteract the vasoconstrictor and 
growth-stimulatory actions of AT1 receptors (14). 
There are several biologically active angiotensin 
metabolites, including angiotensin III, 
angiotensin IV and angiotensin-(1–7), which 
stimulate the AT2 receptors (but with low 
affinity), and/or newly discovered putative 
receptors (14, 15). The physiological relevance of 
these metabolites in various tissues is still under 
investigation. Aldosterone is another effector 
molecule of the RAS, whose synthesis and 
secretion is stimulated by the Ang II mediated 
activation of AT1 receptors in the adrenal zona 
glomerulosa cells. Aldosterone promotes 
sodium reabsorption, water retention, and 
potassium and magnesium loss and modulates 
blood pressure (16). 
Circulating and local (tissue) RAS 
Generally, RAS can be divided to the circulating 
and local (tissue) RAS (17). However, it is very 
hard to differentiate these two systems because 
of their extensive overlap (18). The circulating 
RAS implies renin produced in kidneys, which 
cleaves liver-derived angiotensinogen to 
generate Ang I that is converted by ACE into Ang 
II. On the other hand, a key feature of local RAS 
is the local synthesis of RAS components (e.g. 
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angiotensinogen, Ang peptides) independently 
of the circulating RAS. AT1 and AT2 receptors are 
invariably locally synthesized and are 
components of both circulating and local RAS 
systems (19). In recent years, it has been 
demonstrated that the local RAS includes many 
other potential components that may contribute 
to tissue-specific mechanisms of Ang peptide 
formation, and subsequently may participate in 
the pathophysiology of various diseases or 
contribute to the mechanisms that protect from 
tissue injury. These include the (pro)renin 
receptor(20), Ang generation from Ang-(1-12) 
that is independent of renin (21), intracellular (or 
intracrine) RAS that may contribute to CV 
disease (22, 23), and AT2 receptors and the 
ACE2/Ang-(1-7)/Mas receptor pathway that 
may mediate therapeutic benefit in CV disease 
(22, 23). Furthermore, several novel angiotensin 
peptides have been described, including 
angiotensin IV, angiotensin A, alamandine, and 
angioprotectin (22, 23), which are suggested to 
have the potential to contribute to disease or to 
protective mechanisms. The challenge of future 
research regarding the RAS is to investigate to 
what extent these two components of the RAS 
system are independent of each other, and what 
is the clinical relevance of the local RAS in CV 
disease development and progression. 
Abnormal renin-angiotensin system activity in 
development of cardiovascular diseases 
The RAS also has a central role in mediating and 
regulating vascular adaptive processes (24, 25) 
and is a major regulatory system involved in the 
regulation of a myriad of CV processes. 
Abnormal activity of the RAS leads to the 
development of different CV diseases and 
events (24), and results in vasoconstriction, 
muscular (vascular and cardiac) hypertrophy 
and fibrosis (25). Changed RAS activity is 
involved in secondary hypertension, including 
renin-secreting neoplasms, renovascular 
Figure 1. Physiological feedback loop in renin-angiotensin system – sympathetic nervous system (RAS-SNS) interrelation. 
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hypertension, malignant hypertension, 
pheochromocytoma and primary 
hyperaldosteronism, and by primary 
hypertension, the plasma renin activity (PRA) 
depending on the particular case, can be high, 
normal or low (26). Furthermore, numerous 
signaling pathways, including cell proliferation, 
hypertrophy and apoptosis, in response to Ang II 
are mediated by reactive oxygen species, and 
oxidative stress is deeply associated with the 
progression of CV disease (27). The RAS, through 
its physiological effectors, plays a key role in 
promoting and maintaining inflammation, and 
has proinflammatory and profibrotic effects at 
cellular and molecular levels. Inflammation is an 
important mechanism in the development and 
progression of CV diseases such as 
hypertension and atherosclerosis. A 
dysfunctional endothelium is leaky and 
facilitates migration of inflammatory cells into 
the vascular wall and stimulates smooth muscle 
cells to proliferation (28). Ang II upregulates NF-
κB and related inflammatory genes and 
activates endothelial and endocardial NADPH 
oxidase, which plays a central role in the 
generation of reactive oxygen species (ROS) in 
CV disorders (29). Interestingly, in almost all of 
the above-mentioned states, along with the RAS 
hyperactivity there is increased SNS activity as 
well (30), which sets the potential interaction of 
these two systems in the pathogenesis of CV 
and renal diseases in the focus of recent studies 
in this field. 
The role of the sympathetic nervous system in the 
cardiovascular physiological control system 
Activation of the SNS has long been recognized 
as a manifestation of various CV diseases 
including hypertension and the clinical 
syndrome of heart failure (30). Abnormal 
increase in the circulating plasma 
catecholamines level and increased muscle 
sympathetic nerve activity (MSNA) were some of 
the first documented evidences of increased 
SNS activity in CV disease patients (30). Still, 
even though increased SNS activity was 
generally (systemically) manifested in those 
patients, recent evidences implicate that SNS 
hyperactivity is not uniformly distributed 
through the body, but rather has regional 
distribution differences, with hyperactivity in 
some areas and modest or even absent activity 
in others. Thus, it seems that this generalized 
effect of SNS on the CV system was 
overestimated, and that a special focus of future 
studies should be set on its effect on individual 
organs and organ systems (31). 
Sympathetic nervous system in central nervous 
system 
The regulation of SNS activity in the CNS may 
have a crucial role in the pathogenesis of 
different CV diseases. The main sympathetic 
activity-regulating nuclei in the CNS are the 
paraventricular nucleus in hypothalamus (PVN), 
rostral ventrolateral medulla (RVLM) and 
nucleus tractus solitarius (NTS) (32, 33). NTS 
receives signals from the cardiopulmonary 
afferents, including baroreceptors and 
chemoreceptors, and has an indirect effect on of 
the neuronal activity of the RVLM (32, 33). In 
addition, when activated, NTS leads to the PNV 
activation as well, which is a major integrative 
nucleus that can influence SNS activity and 
extracellular fluid volume by producing 
antidiuretic hormone (ADH), which also has its 
repercussion on the activity of the CV system 
(34). PVN sends signals to RVLM which contains 
sympathetic premotor neurons for the CV 
system, and participates in SNS regulation via 
communication with the intermediolateral 
column of spinal cord (IML) (33, 35). These 
central SNS pathways are a focus of recent 
studies, since it has become more evident that 
the abnormal sympatho-excitation  of the 
central SNS deteriorates renal and CV function 
in various diseases (e.g. chronic kidney disease, 
hypertension, heart failure) and contributes to 
disease progression (30). 
Peripheral sympathetic nervous system 
Peripheral effects of the SNS on the CV system, 
such as short-term—as much as long-term—
control of blood pressure, are quite well known. 
The terminals of sympathetic nerves release 
norepinephrine, which binds to α-adrenergic 
receptors on vascular smooth muscle causing 
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vasoconstriction (36, 37). Many functional studies 
have confirmed that cutaneous blood flow is 
regulated by the SNS (38, 39). Sympathetic 
activity increases cardiac output by releasing 
epinephrine and norepinephrine (40) and also 
has effect on heart rate, which is mediated by 
the release of norepinephrine from 
postganglionic fibers that innervates the whole 
heart. This effect is mediated via β-adrenergic 
receptors on the heart muscle cells (40). Thus, a 
β-adrenergic blockade is an effective treatment 
for elevated blood pressure. The SNS regulates 
short-term transitions in blood pressure by the 
arterial barorefex (41), but also has a significant 
role in long-term blood pressure regulation. 
Studies have shown that the pharmacological 
blockade of sympathetic ganglions decreases 
blood pressure in both hypertensive and 
normotensive subjects (42). Chronic carotid 
baroreceptor stimulation evokes long-term 
reduction in the SNS and blood pressure in 
hypertensive patients (43).  
Another important part of the SNS is a muscle 
SNS. Muscle SNS positively correlated with total 
peripheral resistance, but negatively with 
cardiac output (44). Further, constriction of 
peripheral resistance vessels in the response to 
norepinephrine was lower in subjects with 
higher SNS activity, indicating that healthy 
people with higher muscle SNS had a second 
protective factor to prevent elevation in blood 
pressure (45). These findings may suggest that, 
in regulating the CV system to keep its function 
optimal, SNS activity affects not only well known 
and established pathways, but also many others 
not yet fully comprehensible.  
The kidneys are important targets of 
sympathetic tone modulation in general, since 
the SNS is one of several factors that influences 
the efficiency of the renal regulation of blood 
pressure. Anatomical and physiological 
evidence has shown that the SNS innervates 
JGA cells, renal tubules and vasculature (46, 
47).Thus, changes in renal SNS activity 
frequency mediate increases in urinary sodium 
and water excretion by regulating the renal 
tubular water and sodium reabsorption 
throughout the nephron, changes in renal blood 
flow and the glomerular filtration rate by 
regulating the constriction of renal vasculature, 
and changes in the activity of the RAS by 
regulating the renin release from JGA cells (46, 
47). Increased renal SNS activity decreases renal 
blood flow and the glomerular filtration rate. JGA 
cells in the kidney have β-adrenergic receptors, 
which make the kidneys important targets of 
renal SNS activity and a place where it is 
generally accepted that the “SNS meets the 
RAS” (Figure 1). SNS activity in kidney increases 
renin release by activating JGA β-adrenergic 
receptor, along with an increase in tubular 
sodium reabsorption, and decreases in renal 
blood flow and the glomerular filtration rate (48). 
Furthermore, an additional effect on renal 
circulation is present via response to exogenous 
epinephrine and norepinephrine, with afferent 
arterioles showing higher sensitivity to the 
vasoconstrictive effect of circulating 
catecholamines than efferent arterioles (48). This 
reveals the importance and relevance of SNS 
activity on the kidney's compensatory 
mechanisms and management of volume 
expansion and high salt intake, which precedes 
pathological conditions such as hypertension. 
The SNS also affects the immune system by 
contributing to leukocyte activation and 
extravasation, inflammation, oxidative stress and 
the production of chemokines and cytokines 
(49).  
Thus, it is evident that understanding of the SNS 
modulatory effects on CV function implies its 
general (systemic), central and peripheral 
(individual organ or tissue) effects, and its 
interactions as well.  While these individual 
effects of SNS are mainly well understood, there 
are many intertwined pathways between 
different SNS components in both health and 
disease, which make the effect of the SNS on the 
CV system more complex to understand and 




SEEMEDJ 2017, VOL 1, NO. 1 Implementation of the N - terminal proB-type natriuretic peptide test… 
 
95 Southeastern European Medical Journal, Vol 1, 2017. 
 
Interaction between the renin-
angiotensin system and the 
sympathetic nervous system in the 
pathogenesis of cardiovascular and 
renal diseases 
There are several CV and renal diseases 
characterized by both RAS and SNS activation in 
which these systems, beside their effect on 
blood pressure regulation, also contribute to the 
pathophysiology of both structural and 
functional CV abnormalities and contribute 
significantly to clinical outcome (4). It became 
evident that these systems do not operate 
independently, but interact at different levels 
throughout the CV system. Thus, there is a 
growing effort to clarify the pathophysiological 
mechanisms of interaction and more evident 
mutual potentiation of these two systems in 
different pathological states, including chronic 
kidney disease, essential hypertension, heart 
failure, obesity, metabolic syndrome, etc. 
The renin-angiotensin system and sympathetic 
nervous system interaction in chronic kidney 
disease 
Chronic kidney disease (CKD) is often 
characterized by enhanced activity of the RAS 
and SNS (4), which is summarized in Figure 2A. It 
is considered that kidney ischemia represents a 
central stimulation for renin secretion and RAS 
activation that subsequently increases SNS 
activity. Intravenous infusion of Ang II stimulates 
MSNA in humans, and even a small locus of 
injury in one kidney leads to hypertension 
associated with increased central sympathetic 
activity. Ang II can interact with the SNS on 
different sites, in the kidney, in the CNS and on 
peripheral sites, enhancing norepinephrine 
release from sympathetic nerve activity (50). 
When taken into account that increased SNS 
Figure 2A. Enhancement of renin-angiotensin system activity by sympathetic nervous system and vice versa in cardiovascular 
and renal diseases (chronic kidney disease)  
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activity enhances RAS activation by releasing 
renin from JGE, it is evident that there may be a 
reciprocal potentiation between these two 
systems in the development and progression of 
CKD. Thus, kidney injury, which is generally 
characterized by an increased RAS activity, can 
lead to high SNS activity, hypertension and 
finally end organ damage (50). Moreover, there 
is vast experimental evidence showing that 
increased SNS activity contributes at several 
levels to the development of CV organ damage 
(4, 51, 52). Thus, with these pathophysiological 
mechanisms in mind, it seems logical to 
hypothesize that RAS inhibition would reduce 
SNS activity in CKD. Moreover, recent studies 
reported that a SNS blockade in addition to RAS 
inhibitor treatment might be beneficial in a 
selected patients group (51-53). 
The renin-angiotensin system and the 
sympathetic nervous system interaction in 
chronic heart failure 
Chronic heart failure (CHF) is a multi-factorial 
disease that presents the end result of various 
insults to the myocardium (e.g. ischemic heart 
disease) (3). The most significant hallmark of CHF 
is the continuous interaction between the 
underlying myocardial dysfunction (e.g. 
decrease of cardiac output) and activated 
compensatory mechanisms in order to maintain 
blood pressure and organ perfusion. Activation 
of the RAS along with the SNS plays a crucial 
role in the pathophysiology of CHF, which is 
summarized in Figure 2B. Activation of the SNS 
is considered a major compensatory mechanism 
in the development of CHF, which may be due 
to the changes in peripheral baroreceptors and 
chemoreceptors reflexes, chemical mediators 
Figure 2B. Enhancement of renin-angiotensin system activity by sympathetic nervous system and vice versa in cardiovascular 
and renal diseases (chronic heart failure)  
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that control sympathetic outflow and central 
integrative sites (33) (Figure 2B). In recent years 
Ang II, NO and/or pro-inflammatory cytokines 
were described as crucial mediators controlling 
sympathetic outflow. On the other hand, an 
increase in renin release in CHF state is caused 
by at least two pathways including renal 
sympatho-excitation as well as a decrease in 
renal perfusion pressure (3, 33). All of these 
compensatory mechanisms are initially 
beneficial; however, they became 
counterproductive if sustained for a prolonged 
time (Figure 2B).  
Areas in RVLM and in hypothalamus mediate 
and increase sympathetic outflow in response to 
a microinjection of Ang II, which was inhibited 
after a central infusion of AT1 blocker losartan 
(54-56). Interestingly, this increment in central 
RAS activation could be associated with an 
increased oxidative stress level in CHF state (57, 
58). The role of the central RAS in the supporting 
formation of a vicious circle in the development 
and progression of CHF is not limited to the CNS. 
Francis et al. reported that a central blockade of 
ACE decreased renal SNS activity, improved 
blunted baroreflex sensitivity, and normalized 
sodium consumption, urine sodium and urine 
volume in rats with CHF (59). Furthermore, in a 
myocardial infarction (induced by acute 
coronary artery ligation) rat model with 
transgenic deletion of angiotensinogen (rats 
which express an antisense RNA against 
angiotensinogen), deterioration of CHF was not 
as progressive as in control CHF rats (60). Taken 
together, it became evident that a hyperactive 
central RAS is a contributor to global 
physiological changes as well as the CV 
dysfunction seen in CHF. On the trail of these 
findings there is a growing trend to consider the 
use of both pharmacological and non-
pharmacological therapy targeting the central 
RAS in the treatment of CHF (3). Clearly, the 
described cross talk between the central RAS 
and increased SNS activity is only one potential 
mechanism explaining the regulation of SNS 
activity in CHF (Figure 2B). 
Changes in the renin-angiotensin 
system and sympathetic nervous 
system during high-salt loading 
It is generally accepted that increased dietary 
salt intake is associated with an increase in 
arterial pressure, resulting in hypertension, 
which makes dietary salt a leading cause for CV, 
cerebrovascular, and renal morbidity and 
mortality (61). Various mechanisms were 
suggested to contribute to the development 
and progression of salt sensitive hypertension, 
including increased activation of the RAS and 
elevated SNS activity, well established 
hallmarks of arterial hypertension (62). However, 
in recent years it became more and more 
evident that HS dietary intake affects vascular 
and particularly endothelial functions even in the 
absence of changes in blood pressure (BP) (63-
65).Thus, it should be taken into account that the 
concept of salt-sensitivity is not limited only to 
the effect of dietary salt modulation on BP, but 
to its effect on vascular function and the CV 
system in general as well (63). There is an overall 
consensus that HS intake, high levels of Ang II 
and increased sympathetic activity are all 
injurious to the CV system and play a role in a 
multitude of CV diseases (66). However, much 
less is known about the role of elevated salt 
intake on CV functions that are independent of 
arterial BP, especially in healthy humans. In 
clarifying the pathogenic sequence in which an 
HS diet is on one side and impaired CV function 
(e.g. endothelial dysfunction, hypertension) on 
the other, it is necessary to investigate the effect 
of salt loading on major regulating systems (e.g. 
RAS, SNS) in healthy individuals. 
High salt feedback on the renin-angiotensin 
system 
It has been demonstrated unequivocally in both 
humans and experimental animals that salt 
intake is inversely related to RAS activation: low 
salt intake stimulates RAS activity, and HS intake 
suppresses it (67). Dietary salt intake modulation 
affects RAS activity via at least four different 
pathways including: 1) the macula densa 
mechanism, which regulates renin release in 
response to changes in the renal tubular salt 
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concentration; 2) salt-dependent changes in 
arterial BP; 3) circulating salt-dependent 
hormones, particularly atrial natriuretic peptide 
(ANP); and 4) the SNS (67). Still, signal pathways 
that adjust renin synthesis and RAS activity to 
changes in salt intake are still not completely 
understood. Recent data suggest that macula 
densa mechanism is involved in adjustment of 
renin release in response to acute changes in 
salt loading (68, 69). Still, its effect on RAS 
activation during long-term changes in salt 
loading is less clear: it does not appear to have a 
function in this situation, but rather to modulate 
the general responsiveness of renin release (67, 
70). Furthermore, numerous studies have 
reported that salt-dependent regulation of RAS 
can occur even in the absence of changes in 
arterial BP, especially in healthy individuals (64, 
65, 71). Thus, BP is not a general controller of 
salt-dependent regulation of the RAS under 
normal conditions, but it can modulate renin 
synthesis when salt modulation provokes 
significant changes in BP levels. It has been 
shown that an increase in extracellular volume, 
induced by oral salt intake or intravenous saline 
infusion, is associated with elevated plasma 
levels of atrial natriuretic peptide (ANP), which 
consequently induce natriuresis and 
vasorelaxation, raise glomerular filtration and 
have capacity to directly suppress renin release 
from JGE cells (72). However, whether this 
mechanism is relevant in physiological condition 
in healthy humans or animals is still unclear. 
Studies have reported that modest acute salt 
loading in both healthy humans and animals did 
not elevate ANP levels and did not suppress 
plasma renin activity, indicating that RAS 
inhibition is not dependent on ANP (73, 74). Thus, 
ANP seems inessential for RAS suppression 
during acute salt loading, and its role in long-
term dietary salt modulation should be 
addressed in further investigations. A number of 
studies investigated the correlation between 
salt intake and local renal sympathetic activity, 
indicating an inverse relation between the salt 
intake and renal nerve activity. Since renin-
producing JGE cells have β1-adrenoreceptors 
whose activation results in renin release, one of 
the possible mechanisms mediating RAS 
inhibition by HS loading could be inhibition of 
local renal SNS activity (75, 76). Still, evidence 
indicating that renal nerves have a role as a 
mediator of the salt-dependent regulation of 
renin release and synthesis are insufficient.  
This indisputable connection between salt 
intake and RAS activity indicates that the central 
role in mediating salt homeostasis within the 
body and its effect on CV, cerebrovascular or 
renal function belongs particularly to the RAS. In 
recent years, it became more evident that, 
besides its crucial role in body fluid volume, 
electrolyte balance and blood pressure 
regulation, the normal function of the RAS is 
critical for maintaining arteriolar structure, 
vascular reactivity and cardiovascular health in 
general (5).  HS-induced increased oxidative 
stress (5) and impairment of vascular function 
(that is independent of BP changes) are related 
to low levels of Ang II and a normally functioning 
RAS has a protective effect in the maintenance 
of vascular function (77).  
In contrast to numerous animal studies reporting 
that RAS inhibition provoked an increased 
oxidative stress level and endothelial 
dysfunction, the effect of RAS inhibition on the 
vascular function in a healthy normotensive 
human population was set in a focus of a very 
few recent studies. Most of these studies have 
found that HS intake (RAS inhibition) impairs the 
flow mediated dilation of the brachial artery in 
the absence of BP changes (65), which was likely 
associated with reduced vascular NO bioactivity 
(78-80). Furthermore, same deleterious effect of 
acute salt loading was observed in skin 
microcirculation as well (64, 65, 79).  Cavka et al. 
reported that one week of a low-salt diet with 
oral losartan (a selective AT1 receptor inhibitor) 
administration led to a significant increase in 
plasma levels of the cyclooxygenase 
dependent vasoconstrictor thromboxane (TXA2) 
without causing any changes in BP and/or skin 
microvascular blood flow responsiveness in 
young healthy women, suggesting that an AT1 
receptor blockade may play an important role in 
the regulation of a cyclooxygenase-dependent 
pathway of metabolism of arachidonic acid (81). 
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High salt feedback onsympathetic nervous 
activity 
Sodium retention is link between CV and 
renovascular diseases together with elevated 
SNS activity (3, 4). Interestingly, it still remains to 
be investigated how salt intake affects SNS 
activity in healthy individuals in the absence of 
BP changes (does it inhibit or potentiate SNS 
activity), and whether this effect is uniform for 
both local and systemic SNS responses (Figure 
1). There is a paucity of studies investigating the 
effect of HS loading on systemic SNS activity in 
physiological conditions, both in animal and 
human models. So far, studies in animal models 
(rabbits) have reported that HS alone had no 
effect on baseline BP, water intake or SNS 
activity, but in combination with low-dose Ang II 
infusion HS provoked sympatho-excitation (82). 
HS intake induces the central sensitization of 
sympathetic circuits to result in exaggerated CV 
reflexes and an increase in BP variability in 
normotensive salt-resistant animals (83). 
Furthermore, a 6-day HS diet increased the 
mean systolic BP, decreased  heart rate, and 
increased vagal activity in healthy, normotensive 
women (age 40–70) (84). These very few studies 
suggest that changes in autonomic nervous 
system balance should be taken into account 
during RAS modulation by salt intake, even in 
young healthy normotensive individuals. 
Regarding potential mechanisms that mediate 
interaction between salt intake and SNS activity, 
it is well known that acute increase of plasma 
osmolality of sodium concentration in both 
plasma and cerebrospinal fluid can cause an 
increase of SNS activity (85, 86), which is 
presumably mediated by osmosensory neurons 
in the organum vasculosum laminae terminalis 
(OVLT) in the brain (86). The most recent study 
by Kinsman et al. has demonstrated that OVLT 
neurons are activated by modest rises in plasma 
or cerebrospinal NaCl, and their activation 
elevates BP and triggers a pattern of SNS activity 
that presumably facilitates renal sodium 
excretion in Sprague Dawley rats (87). 
Furthermore, many other agents, such as 
endogenous ouabain are involved in blood 
pressure (BP) elevation. Elevated sodium 
concentrations in body fluids can induce the 
secretion of the ouabain by both the 
hypothalamus and the adrenals, suggesting that 
ouabain could have an important role in linking 
together central and peripheral hypertension 
occurrences (88). Ouabain acts centrally in the 
brain to increase the sympathetic drive (89) and 
in the periphery causing vasoconstriction via 
myocytes and endothelium (90). Still, when 
taken into account that in most studies (both 
animal and human) in which moderate HS 
loading provoked vascular dysfunction 
independently of BP changes, there was no 
significant increase in sodium concentration in 
plasma. The above suggested effects of the 
described conditions are disputable and remain 
in need of clarification. 
Another intriguing relation is that between the 
SNS and RAS during HS intake. An inverse 
relation of HS intake and renal SNS activity was 
observed (91, 92), showing that HS intake can 
suppress renal SNS activity. Renal SNS activity 
also affects RAS, whereas renal SNS activity 
stimulates renin release via the activation of β1 
adrenoceptors placed in renin-producing JGE 
cells (75, 93), as already described. To examine 
this axis, studies using β1/β2 double knockout 
mice fed with a HS diet were performed (94). In 
this study β1/β2 double knockout mice were fed 
with a HS diet, and surprisingly they maintained 
the salt-dependent regulation of renin plasma 
concentration, since low salt intake stimulated 
renin release, and HS intake suppressed it (94). 
Similarly, dogs were fed with a HS diet and the 
changes in SNS activity effects were 
investigated via modulating baroreceptor 
activity (95). The suppression of central SNS 
activity by electrical stimulation of 
baroreceptors lowered BP without affecting the 
RAS and without impairing the normal salt-
dependent secretion of renin. This may suggest 
that neither renal nor central SNS activity is 
crucial in the salt-dependent regulation of the 
RAS, but surely acts as a moderator in the RAS 
response to changes in salt load (67). Since most 
organs possess a local RAS that is regulated 
independently and is somewhat 
compartmentalized from the circulation, it has 
been suggested that the brain RAS may play an 
important role in CV regulation through its ability 
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to modulate SNS activity (96) (Figure 1). Studies 
in animal models have shown that increased 
levels of brain Ang II and the activation of brain 
AT1 receptors in the RVLM mediate the 
sympatho-excitatory actions (96). To date, the 
limited data indicate that elevated dietary salt 
intake enhances both sympatho-excitatory and 
sympatho-inhibitory responses evoked by a 
number of neurotransmitters exogenously 
applied to the RVLM (97-99), but these 
enhanced responses could not be attributed to 
changes in downstream sympathetic pathways 
or vascular reactivity (98-100). On the other 
hand, results obtained in studies on 
experimental animals have demonstrated that 
the brain Ang II activates posterior hypothalamic 
nuclei that increase efferent renal nerve activity 
and BP, suggesting the presence of 
renal/cerebral interaction in which the brain RAS 
can regulate the peripheral sympathetic activity 
and renal RAS (101).  
Taken together, the relation between SNS 
activity and salt intake and its role in the 
development and progression of hypertension is 
yet unclear. 
Conclusions 
Many separated parts and mechanisms of the 
RAS and SNS affecting the CV system are 
discovered and explained, but the interplay of 
these separated mechanisms seems to have a 
pivotal role in explaining and understanding this 
highly interactive network. Studies conducted so 
far may suggest that some parts of the RAS 
and/or SNS effect on the CV system are 
overestimated, while others are underestimated. 
In a situation such as HS intake, both RAS and 
SNS activity may have a modulatory, 
compensatory role, and this role can increase as 
the CV and renovascular diseases progress. 
metabolic syndrome and a series of 
cardiovascular problems (35), it is very important 
that the values were within healthy limits. Some 
researches show that, similar to BMI, values for 
PBF and WHR rise as people age (36). 
The body composition (presented in Table 1) of 
the subjects shows that they have appropriate 
mass of fat and muscles, and their body 
composition is in accordance to weight status 
based on BMI value. In other words, the 
prevalence of obesity based on BMI distribution 
would probably be similar if they were 
distributed according to the BF% or SLM. Results 
reported by Grygiel-Gorniak et al. (37) show 
similar values of BMI, WHR and BF% with the 
results of the present study, as well as the similar 
differences between sexes. Our findings 
regarding differences in BMI and BF% between 
men and women showed that men had higher 
BMI, but lower BF% compared to women. This 
could be ascribed to the greater muscle mass in 
men. However, the correlation between BF% and 
BMI showed a statistically significant high 
positive value, indicating a strong connection 
between those two variables. Correlation was 
slightly lower in men than in women. There was 
also high correlation between BF% and WHR in 
both sexes. Collins et al., in their study of 
association of BMI and BF% among BMI-defined 
non-obese middle-aged individuals, found that 
the BMI category was not concordant with the 
%BF classification for 30% of the population. The 
greatest discordance between %BF and BMI was 
observed among %BF-defined 
overweight/obese women (38). A strong 
correlation of BMI and BF% in young women was 
reported in the study of Bakir et al. (39). They 
obtained correlation coefficients between BMI 
and BF% of 0.74 for women aged 18-30 years. 
Proportions of weight categories were not 
significantly different over the years in which 
measurements were made. Students that 
choose to attend the College of Applied 
Sciences in Vukovar are similar in weight status 
throughout the years. This result is different 
compared to predictions of increase in obesity 
prevalence, and shows a steady state in the 
weight status of first-year students during the 
years examined, without any increase of obesity. 
It is possible, however, that it might have been 
too short a period for potential trends to reveal 
themselves. 
Based on the presented results, the conclusion 
could be made that most of the freshman 
students at the College of Applied Sciences fall 
in the category of normal weight, with an 
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overweight prevalence of around 19-20%, 
including around 5% obese persons among 
them. There are also 6.5% of those who are 
underweight. There is a higher tendency toward 
the prevalence of overweight persons among 
men, while among women there is a higher 
tendency for underweight prevalence. The 
prevalence of obesity and the overall 
distribution across the weight categories, as well 
as the body composition of the first-year 
students have not changed during the period 
from 2008 to 2016.  
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